Q-omics provides the consensus-scored ZMYM2 profile across patient tissues and cancer cell-line models. ZMYM2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZMYM2 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ZMYM2 protein abundance shows 23,518 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, KICH, and LSCC as cancer lineages where ZMYM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMYM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMYM2 survival associations across molecular data types. ZMYM2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMYM2 RNA expression–survival associations across cancer types. High ZMYM2 expression shows unfavorable associations in CESC, UVM, ACC and LIHC, but favorable associations in KIRP and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZMYM2 RNA expression.
This table summarizes ZMYM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZMYM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMYM2 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, BLCA, CHOL and LIHC. The KICH box plot shows higher ZMYM2 RNA expression in normal versus tumor tissue (log2 FC = −1.457, t-test p < 0.001).
This table shows molecular features associated with ZMYM2 in patient tissues and cancer cell lines. In patient samples, ZMYM2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMYM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
